Increases in gonorrhoea incidence and GUM clinic waiting times: are we in a vicious circle like
 the late 1990s and early 2000s, but now exacerbated by drug resistance?

3

I read the paper of Foley et al. (*Inequalities in access to genitourinary medicine clinics in the UK: results from a mystery shopper survey*. Sex Trans Infect Sex Online First: 04 April 2017) with
concern.

Delays in treating symptomatic patients typically indicate insufficient service capacity, creating a vicious circle where delayed (or lack of) treatment causes onward transmission, increased incidence, and continuing unmet treatment need.[1] Increased treatment capacity (complemented by condom promotion and other prevention activity) is required to break the vicious circle and enter a virtuous circle where prompt treatment averts transmission and reduces future treatment need – improving health and ultimately saving money. This situation occurred from the late 1990s, when diagnoses and treatment delays increased markedly until investment was made to regain control.

14 Foley et al.'s findings, combined with increasing gonorrhoea diagnoses, suggest that we are in a 15 vicious circle once again. However, this time it is much more serious, due to the growing problem of 16 drug resistance, with gonorrhoea being on WHO's list of priority pathogens requiring new antibiotics 17 (http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/). Increased 18 transmission means greater numbers of infections of already-resistant, hard-to-treat gonorrhoea, 19 which are at risk of further transmission due to failure of initial treatment. Furthermore, greater 20 numbers of infections result in more treatment events, each being an opportunity for selection for 21 resistance, including multidrug resistance in already monoresistant strains.[2]

It is more important than ever to diagnose and treat cases promptly, and for contact tracing to identify asymptomatic infections, which can be an important infection reservoir leading to onward transmission, and whose role in the dynamics of drug resistance is not understood.[2] Faster action to regain control means a smaller cost and greater net benefit.[1]

Finally, further research into gonorrhoea's natural history, epidemiology, and evolution is urgentlyrequired.[2]

28

- 29 Yours faithfully
- 30 Dr Peter J White

31 MRC Centre for Outbreak Analysis and Modelling and NIHR Health Protection Research Unit in

32 Modelling Methodology, Imperial College London School of Public Health, London W2 1PG, UK

- 33 Modelling and Economics Unit, National Infection Service, Public Health England, London NW9
- 34 5EQ, UK
- 35
- 36 <u>References</u>
- 37 1. White PJ, Ward H, Cassell JA, Mercer CH, Garnett GP. Vicious and virtuous circles in the
- 38 dynamics of infectious disease and the provision of health care: gonorrhea in Britain as an example. J
- 39 Infect Dis 2005; 192: 824–836.
- 40 2. Grad YH, Goldstein E, Lipsitch M, White PJ. Improving control of antibiotic resistant gonorrhea
- 41 by integrating research agendas across disciplines: key questions arising from mathematical modeling.
- 42 J Infect Dis 2016; 213(6): 883–890.
- 43
- 44 <u>Funding</u>
- 45 The author thanks the Medical Research Council (grant MR/K010174/1) and the National Institute for
- 46 Health Research Health Protection Research Unit (NIHR HPRU) in Modelling Methodology at
- 47 Imperial College London in partnership with Public Health England (PHE) (grant HPRU-2012-
- 48 10080) for funding. The views expressed are those of the authors and not necessarily those of the
- 49 Department of Health, MRC, NHS, NIHR, or Public Health England.
- 50